The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581.
A. P. Venook
Consultant or Advisory Role - Genomic Health (U); Myriad Genetics (U)
Research Funding - Genomic Health
D. Niedzwiecki
No relevant relationships to disclose
M. Lopatin
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
M. Lee
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
P. N. Friedman
No relevant relationships to disclose
W. Frankel
No relevant relationships to disclose
K. Clark-Langone
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
C. Yoshizawa
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
C. Millward
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
S. Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
R. M. Goldberg
Consultant or Advisory Role - Genentech; Lilly
Research Funding - Abbott Laboratories; Amgen; Bayer; Bristol-Myers Squibb; Genentech
N. N. Mahmoud
No relevant relationships to disclose
R. L. Schilsky
Consultant or Advisory Role - Foundation Medicine
M. M. Bertagnolli
No relevant relationships to disclose